Generic versions remain 5 to 7+ years away, but manufacturer competition and government pressure are driving prices lower faster than the patent timeline alone would suggest
With a clear plan and the right support, you can protect the progress youve made and move forward with confidence
While mild gastrointestinal issues like nausea and diarrhea were common side effects, there was no direct link to fatalities during the trials
One notable difference: semaglutide and tirzepatide have established prescribing information with FDA-approved dose ranges and flexibility for clinicians to hold patients at intermediate doses if tolerability is an issue
The medication is doing the hard work of reducing cravings
[44][48] Addiction GLP-1s are showing significant promise in treating addiction , with studies indicating they reduce cravings for alcohol, nicotine, cannabis, and opioids by modulating brain reward systems